Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.

doi:10.1001/jamaoncol.2018.1778

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.

JAMA oncology - 1 Oct 2018

Luen Stephen J, Asher Rebecca, Lee Chee Khoon, Savas Peter, Kammler Roswitha, Dell'Orto Patrizia, Biasi Olivia Maria, Demanse David, JeBailey Lellean, Dolan Sinead, Hackl Wolfgang, Thuerlimann Beat, Viale Giuseppe, Colleoni Marco, Regan Meredith M, Loi Sherene

Abstract excerpt

Importance: A range of somatic driver alterations has been described in estrogen receptor-positive, HER2-negative (ER+/HER2-) early breast cancer (BC); however, the clinical relevance is unknown. Objective: To investigate associations of driver alterations with prognosis and the role of PIK3CA mutations in prediction of benefit associated with endocrine therapy in postmenopausal patients with ER+/HER2- early BC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase Inhibitors

Share to Class I Phosphatidylinositol 3-Kinases

Share to Double-Blind Method

Share to Postmenopause

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 29902286
DOI: 10.1001/jamaoncol.2018.1778
PMCID: PMC6233777

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.PMID 29902286Read ↗

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.Semantic proximity Read ↗

Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.Semantic proximity Read ↗

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read ↗

Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.Semantic proximity Read ↗

Comparison of the Mutation Profiles of Triple-Negative Breast Cancers and Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers at the T2N0-1M0 StageSemantic proximity Read ↗

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific TreatmentsSemantic proximity Read ↗

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read ↗

Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.Semantic proximity Read ↗

Clinical Genomic Profiling to Identify Actionable Alterations for Very Early Relapsed Triple-Negative Breast Cancer Patients in the Chinese PopulationSemantic proximity Read ↗

Genetics: Defining driver mutations in the genomic landscape of breast cancer.Semantic proximity Read ↗

The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.Semantic proximity Read ↗

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.